SAN FRANCISCO, CA—Lennart Mucke, MD, who directs neurological research at the Gladstone Institutes, today received the MetLife Foundation’s 2013 Award for Medical Research in Alzheimer’s Disease at a scientific briefing and awards ceremony in New York.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes have discovered that a certain type of DNA damage long thought to be particularly detrimental to brain cells can actually be part of a regular, non-harmful process.
San Francisco, CA—The most devastating aspect of Parkinson’s disease may not be its debilitating symptoms, which rob its victims of their ability to control their own movement. It may not be the millions around the world and their families who suffer each day from the disease’s harmful effects.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes are recommending a shift in efforts to treat Alzheimer’s disease by developing drugs that target the apoE4 protein, which has long been associated with an increased risk for the disease.
CAMBRIDGE, MA and SAN FRANCISCO, CA—The ALS Therapy Development Institute (ALS TDI) and the Gladstone Institutes today announced the formation of a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes have defined for the first time a key underlying process implicated in multiple sclerosis (MS)—a disease that causes progressive and irreversible damage to nerve cells in the brain and spinal cord.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes and the Stanford University School of Medicine have discovered how modifying a gene halts the toxic buildup of a protein found in nerve cells. These findings point to a potential new tactic for treating a variety of neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease)—a fatal disease for which there is no cure.
SAN FRANCISCO, CA—Using animal models, scientists at the Gladstone Institutes have discovered how a protein deficiency may be linked to frontotemporal dementia (FTD)—a form of early-onset dementia that is similar to Alzheimer’s disease.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes have discovered that an FDA-approved anti-epileptic drug reverses memory loss and alleviates other Alzheimer’s-related impairments in an animal model of the disease.
SAN FRANCISCO—July 15, 2012—Lennart Mucke, MD, who directs neurological research at the Gladstone Institutes, has received the Khalid Iqbal Lifetime Achievement Award for his exceptional contributions to Alzheimer's disease research. The Alzheimer's Association presented the award to Dr.